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A B S T R A C T
Nearly half of the world’s population is infected with Helicobacter pylori. Clinical manifestations of this infection
range from gastritis and peptic ulcers to gastric adenocarcinoma and lymphoma. Due to the emerging of anti-
biotic resistant strains and poor patient compliance of the antibiotic therapy, there is increasing interest in the
development of a protective vaccine against H. pylori infection. The bacterial protein FliD forms a capping
structure on the end of each ﬂagellum which is critical to prevent depolymerization and structural degradation.
In this study, the potential of FliD as a prospective H. pylori subunit vaccine was assessed. For this purpose,
immunogenicity and protective eﬃcacy of recombinant FliD (rFliD) from H. pylori was evaluated in C57BL/6
mice. Puriﬁed rFliD was formulated with diﬀerent adjuvants and administered via subcutaneous or oral route.
Subcutaneous immunization with rFliD elicited predominantly mixed Th1 and Th17 immune responses, with
high titers of speciﬁc IgG1 and IgG2a. Splenocytes of immunized mice exhibited strong antigen-speciﬁc memory
responses, resulting in the secretion of high amounts of IFN-γ and IL-17, and low levels of IL-4. Immunization
with rFliD caused a signiﬁcant reduction in H. pylori bacterial load relative to naïve control mice (p < 0.001),
demonstrating a robust protective eﬀect. Taken together, these results suggest that subcutaneous vaccination
with rFliD formulated with CpG or Addavax could be considered as a potential candidate for the development of
a subunit vaccine against H. pylori infection.
1. Introduction
H. pylori is a spiral-shaped, extracellular Gram-negative, and mi-
croaerophilic bacterium that has colonized the stomach of approxi-
mately 50% of the worldwide human population (Correa and Piazuelo,
2011). In 1994, H. pylori was classiﬁed as a class I carcinogen by the
World Health Organization (Anderl and Gerhard, 2014). Infection is
strongly associated with the development of several gastrointestinal
diseases, including duodenal and gastric ulcers, gastric adenocarcinoma
and gastric mucosa-associated lymphoid tissue lymphoma (MALT)
(Suzuki et al., 2009). Antibiotic therapy, although eﬀective, is asso-
ciated with several disadvantages including low patient compliance due
to the drugs’ side eﬀects, treatment failure as a result of the emergence
of drug-resistant strains, high costs, and the failure to prevent reinfec-
tion (Boyanova et al., 2002; Frenck and Clemens, 2003; Gisbert, 2005;
Wheeldon et al., 2005). Therefore, alternative approaches to combat H.
pylori infection are currently being pursued, including vaccination.
Several H. pylori proteins have been identiﬁed as immunogenic in
preclinical models, including Urease B (UreB) (Yang et al., 2005), Va-
cuolating toxin A (VacA) (Ghiara et al., 1997), H. pylori adhesion A
(HpaA) (Sutton et al., 2007), neutrophil-activating protein A (NapA)
(Satin et al., 2000), outer membrane protein (Omp) (Czinn and
Blanchard, 2011), cytotoxin-associated antigen (CagA) (Ghiara et al.,
1997), heat-shock proteins (Hsp) (Chionh et al., 2014a; Ferrero et al.,
1995), OipA (Chen et al., 2012) catalase (Radcliﬀ et al., 1997) and
chimeric genes (Zhang et al., 2015; Li et al., 2012; Lv et al., 2014). Each
of these antigens has the ability to reduce the bacterial load in animal
models, but the elicited protection provided by them is less than ideal.
Current strategies to enhance vaccine eﬃcacy include the identiﬁcation
of most suitable immune targets and the combination of im-
munodominant antigens into multivalent formulations. Khalifeh Gholi
et al. (Khalifeh Gholi et al., 2013) demonstrated that FliD, the ﬂagellar
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hook-associated protein 2, reacts with approximately 97 percent of sera
obtained from patients infected with H. pylori, but not with sera from
uninfected individuals, and reacts very weakly with sera from patients
whose infections had been eradicated, suggesting that this is a common
immune target in the infected human host (Khalifeh Gholi et al., 2013).
FliD plays a crucial role in ﬂagella assembly. Flagellin is important for
bacterial motility and is essential for colonization and persistence of H.
pylori in the stomach niche (Eaton et al., 1996).
The objective of the current study was to investigate the protective
eﬃcacy and underlying mechanisms of recombinant FliD (rFliD) an-
tigen. Owing to inherent safety and the low risk of adverse reactions
(Ghasemi et al., 2015), protein subunit immunization is an attractive
vaccination approach. However, immune responses elicited by the ad-
ministration of pure antigens are usually low. Therefore, we in-
vestigated whether formulations of FliD with diﬀerent adjuvants, CpG,
Cholera toxin subunit B (CTB), or Addavax, enhance protection of mice
against H. pylori infection.
2. Materials and methods
2.1. Bacterial strains
E. coli strains BL21 and TOP10 were used for expression of FliD.
Bacteria were routinely grown at 37 °C in LB broth or agar. The H. pylori
strain SS1 was grown on Brucella agar supplemented with 5% sheep
blood, 5 μg/mL trimethoprim, 161.5 μg/mL polymyxin B (Sigma),
10 μg/mL vancomycin (sigma) and 2.5 μg/mL amphotericin B (Sigma),
in an anaerobic jar with microaerophilic gas generating kit (Merck,
Germany) for 3 days at 37 °C. For infection experiments, bacteria were
subcultured in brain heart infusion broth (BHI, Merck) containing
10 μg/mL vancomycin and supplemented with 10% Fetal Bovine Serum
(FBS) (Sigma), and grown in microaerophilic conditions for 72 h at
37 °C.
2.2. Cloning, expression, and puriﬁcation of recombinant FliD
Cloning and expression of FliD from H. pylori in BL21 (DE3) and its
puriﬁcation has been described previously (Khalifeh Gholi et al., 2013).
Brieﬂy, the ﬂid gene was ampliﬁed from genomic DNA of H. pylori by
PCR (forward primer: 5′-ATGGCAATAGGTTCATTAAGCT-3′, reverse
primer: 5′- ATTCTTTTTAGCCGCCGCTT-3′). The DNA fragment was
directly inserted into pTZ57R (InsTAclone PCR Cloning Kit, Thermo-
Fisher, USA) and then subcloned into the pET28a+ vector (Novagen,
USA) to add a 6xHis tag. To express FliD, 1mM isopropyl-β-D-thioga-
lactopyranoside (IPTG) was used. Upon induction, rFliD was expressed
in soluble form and puriﬁed under native conditions. Following SDS-
PAGE separation, purity and identity of the recombinant protein was
evaluated by Coomassie blue staining and Western blotting (Ghasemi
et al., 2014a; Ghasemi et al., 2013). For immunodetection, size-sepa-
rated proteins were transferred to a PVDF membrane and rFliD detected
using anti-6xHis peroxidase (Roche, Germany) (1/40,000). Finally, the
membrane was developed using 3, 3′-Diaminobenzidine tetra-
hydrochloride (Sigma). To preclude eﬀects caused by residual
endotoxin present in the protein preparation, only batches of puriﬁed
protein with an endotoxin content of less than 0.05 endotoxin units per
mg of protein (evaluated by Limulus amebocyte lysate analysis kit,
Lonza, Basel, Switzerland) were used in further studies. The Bradford
method was used to determine the concentration of the recombinant
protein (Stoscheck, 1990).
2.3. Mice
Six- to eight-week-old female C57BL/6 mice were purchased from
the Pasteur Institute of Iran and maintained under speciﬁc pathogen-
free conditions. Mice were handled under optimal conditions of tem-
perature, hygiene, humidity and light (cycles of 12 h dark/light). All
experimental animal procedures were approved by the ethical com-
mittee of the Kashan University of Medical Science.
2.4. Immunization and H. pylori inoculation of mice
One hundred and forty-four mice were randomly divided into eight
groups (n= 18 each). Five groups were immunized subcutaneously
(s.c.) three times at 2-week intervals with either 30 μg rFliD formulated
with 20 μg/mouse CpG (CpG, ODN1826 5ʹ-TCCATGACGTTCCTGAC
GTT- 3ʹ, synthesized by TAG Copenhagen, Denmark), 30 μg rFliD for-
mulated with (1:1) Addavax (Invivogen, USA), or PBS, or 20 μg/mouse
CpG, Addavax, and PBS alone. The two remaining groups were orally
immunized with rFliD and 20 μg/mouse CTB (Sigma, Germany) or CTB
alone (Table 1). To enable immunization in a small volume, the re-
combinant antigen was lyophilized and then reconstituted in a volume
of 100 μl PBS containing the respective adjuvant.
Two weeks after the ﬁnal immunization, eight mice from each
group were challenged orally thrice in 2-day intervals with 5× 108
CFU mouse-adapted H. pylori strain SS1 in 100 μl brain heart infusion
broth. Five mice were bled to obtain sera at days 0, 15, 30, 45, and 75
after the ﬁrst immunization. The remaining ﬁve mice were sacriﬁced to
evaluate immune responses including cytokine production, sIgA secre-
tion, and IgG immune responses on the day of the challenge. For
measuring sIgA secretion, gastric ﬂuid was collected as described pre-
viously (Chionh et al., 2014b).
2.5. Humoral and mucosal immune responses
To measure rFliD-speciﬁc serum IgG1, IgG2a and gastric ﬂuid sIgA
titers in immunized mice, an enzyme-linked immunosorbent assay
(ELISA) was used. 96-well polystyrene plates (Greiner Bio-One,
Frickenhausen, Germany) were coated with the puriﬁed rFliD (1 μg/
mL). After overnight incubation, TBST buﬀer (Tris-buﬀered saline, pH
7.4, and containing 0.05% Tween 20) were used to wash the plates
three times followed by blocking with 300 μl 10% FBS in PBS for 2 h at
37 °C. After that, plates were incubated with serial dilutions of mouse
sera or gastric and intestinal ﬂuid for 2 h at room temperature and then
washed. HRP-conjugated goat-anti-mouse IgG1, IgG2a or sIgA anti-
bodies (BD Pharmingen, USA) were added to the wells for another
90min at 37 °C. After the last washing step, speciﬁc reactivity was
Table 1
Vaccine formulations and route of application.
Route Vaccine Antigen dose Adjuvant dose Total volume Number of mice
Subcutaneous rFliD+ CPG 30 μg 20 μg 100 μl 18
rFliD+Addavax 30 μg 50 μl 100 μl 18
rFliD+PBS 30 μg 0 100 μl 18
CpG 0 20 μg 100 μl 18
Addavax 0 50 μl 100 μl 18
PBS 0 0 100 μl 18
Oral rFliD+CTB 30 μg 5 μg 100 μl 18
CTB 0 5 μg 100 μl 18
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measured by the addition of 50 μl/well of the enzyme substrate TMB
(Pishtaz Teb, Tehran, Iran). The reaction was stopped by adding 30 μl
20% H2SO4 to each well. Optical density at 495 nm was measured using
an ELISA plate reader (Bio-Tek Instruments, Winooski, USA).
2.6. Cellular immune responses
Assessment of cellular immune responses has been described else-
where (Ghasemi et al., 2015; Ghasemi et al., 2014b). Brieﬂy, ﬁfteen
days after the last immunization, the mice were euthanized and spleens
removed under sterile conditions. The spleens were minced and
homogenized and then mononuclear cells (MNCs) were isolated by Fi-
coll–Paque (GE Healthcare, Uppsala, Sweden) density centrifugation.
2× 106 splenocytes were plated in one well of a 24-well plate in 2ml of
complete medium (RPMI-1640 supplemented with 2mM L-glutamine,
100 U/ml penicillin, 100 μg/mL streptomycin and 10% heat inactivated
FBS) and 10 μg/mL rFliD were added to each well and the plates in-
cubated at 37 °C in 5% CO2 for 48 h. Control wells received PBS instead
of the antigen. After 48 h, supernatants were collected and stored at
−70 °C for cytokine assay. Concentrations of interferon-gamma (IFN-γ),
interleukin-17 (IL-17), and −4 (IL-4) were determined by ELISA ac-
cording to the manufacturer’s instructions (R&D Systems, USA).
2.7. Protection experiments
H. pylori CFU were quantiﬁed six weeks after the last immunization.
For this purpose, the copy number of H. pylori 16 s gene within mouse
gastric tissues was measured by a quantitative PCR as described pre-
viously (Roussel et al., 2007). A recombinant plasmid carrying the H.
pylori 16S gene was used as a standard to measure copy numbers of the
16S gene in DNA extracted from half of a mouse stomach and the ob-
tained Colony-Forming Units (CFU) calculated as CFU per stomach.
2.8. Statistical analysis
Statistical analysis was carried out using SPSS computer software,
version 16.0. All data were represented as the mean ± standard de-
viation (SD). Diﬀerences among data of the ﬁve groups were analyzed
by one factor analysis of variance (ANOVA) and Tukey’s post hoc test in
SPSS. P-values< 0.05 were considered as statistically signiﬁcant.
3. Results
3.1. Expression and puriﬁcation of the recombinant FliD protein
To obtain suﬃcient amounts of rFliD for protection experiments and
immunological analyses, the H. pylori ﬂid gene was ampliﬁed by PCR
and fused to a 6 x histidine tag in the pET28 bacterial expression vector.
E.coli BL21 cells were transformed with the resulting plasmid, and
protein expression was induced with IPTG. Upon puriﬁcation with Ni-
NTA agarose, rFLiD expression product was veriﬁed via SDS-PAGE and
Western blot (Ghasemi et al., 2013). Consistent with molecular weight
prediction, recombinant rFliD had a size of approximately 84 kDa
(Fig. 1). From one liter of liquid culture, approximately 35mg of rFliD
protein was obtained.
3.2. Subcutaneous vaccination with rFliD formulated with adjuvants
provides protection against H. pylori infection
To investigate whether immunization with rFliD provided protec-
tion against subsequent infection with H. pylori, groups of mice were
immunized with rFliD formulated with diﬀerent adjuvants, rFliD alone,
or PBS. Two weeks after the last immunization, mice were challenged
thrice at one day intervals with 5×108 H. pylori SS1. Bacterial DNA
load was assessed by qPCR four weeks post infection.
The copy numbers of H. pylori DNA in groups immunized with rFliD
formulated with adjuvants were signiﬁcantly lower than in mice im-
munized with rFliD in PBS or control mice. The highest degree of
protection among animals vaccinated with rFliD plus adjuvants was
observed in mice vaccinated with rFliD plus CpG, albeit without
reaching statistical signiﬁcance (Fig. 2). Compared to the negative
control group, even mice vaccinated with rFliD in PBS showed a sig-
niﬁcant reduction in CFU, implicating a high immunogenicity of this
antigen.
3.3. Vaccination with rFliD and adjuvants induces vigorous antibody
responses
Speciﬁc antibody titers produced in mice immunized with rFliD
formulated with diﬀerent adjuvants were evaluated by ELISA in sera
obtained at diﬀerent time points after the ﬁrst immunization.
Vaccination with rFliD induced strong immunoglobulin G (IgG) re-
sponses, with IgG1 titers usually exceeding those of the IgG2a subtype
(Fig. 3). The IgG1/IgG2a ratio was 1–2 and 1–3.44 in mice immunized
subcutaneously and orally, respectively. These results suggested that
CpG and Addavax induced a Th1-biased immune response.
Although diﬀerent immune responses were observed for CpG and
CTB, the total amount of IgG detected was similar for both adjuvants.
Responses induced in mice orally immunized with rFliD formulated
with CTB were markedly lower than in mice immunized subcutaneously
with rFliD plus CpG or Addavax. However, the IgG responses of mice
immunized with rFliD formulated with CTB were signiﬁcantly in-
creased 75 days after the initial immunization. Mice vaccinated with
rFliD formulated with either CpG or Addavax demonstrated increased
IgG1 and IgG2a titers commencing at the second week post-immuniza-
tion, peaking at the sixth week and remaining elevated until the ele-
venth week after the ﬁrst immunization. Compared to all adjuvant
formulations, rFliD alone induced only low titers of both IgG1 and IgG2a
antibodies in immunized mice (Fig. 3). To assess the mucosal immune
responses elicited by immunization, gastric ﬂuid IgA production was
determined for each vaccine. As shown in Fig. 3, the three groups im-
munized with rFliD plus adjuvants showed signiﬁcantly elevated gastric
mucosal IgA titers compared to the control group which had only re-
ceived PBS (P < 0.001). The group immunized with rFliD and PBS
exhibited no diﬀerence when compared to the PBS control group.
Taken together, these ﬁndings suggest that the combination of rFliD
with CpG, Addavax, or CTB induced robust antibody responses.
3.4. Vaccination with rFliD and adjuvants elicits a mixed Th1 and Th17
type of immune response
To further characterize the induced immune responses, splenocytes
from mice immunized with rFliD formulated with diﬀerent adjuvants,
or rFliD alone, or PBS were isolated 45 days after the ﬁrst immuniza-
tion. Following incubation with rFliD, cytokine production was as-
sessed. Secretion of IFN-γ, IL-4, and IL-17 from splenocytes of im-
munized mice after re-stimulation was assessed two weeks after the
ﬁnal immunization boost. As shown in Fig. 4, the concentrations of all
tested cytokines were signiﬁcantly increased in mice vaccinated with
rFliD formulated with adjuvants compared to the PBS control group, yet
the amount of IL-4 was comparable low. Splenocytes of mice im-
munized with rFliD without adjuvants secreted signiﬁcantly higher
amounts of IFN-γ and IL-17 than splenocytes from PBS control mice.
These results indicate that rFliD alone is capable of eliciting cellular
immune responses mostly of Th1 and Th17 type. Moreover, these im-
mune responses were markedly enhanced by the use of adjuvants.
It is important to note that there were no discernable diﬀerences in
the patterns of cytokines secreted by splenocytes from mice immunized
with rFliD formulated with the three diﬀerent adjuvants (Fig. 4).
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4. Discussion
The development of an eﬀective vaccine against H. pylori has been
confounded by several aspects including choice of the antigen, route of
vaccination, and selection of adjuvants to boost immunogenicity (Li
et al., 2015; Brown et al., 2014). Motility enables H. pylori to reach the
gastric epithelium, attach via adhesion factors, and establish infection
in the epithelium (Sheu et al., 2010). Polar ﬂagella is considered an
important virulence factor for H. pylori, as studies done with a non-
motile ﬂiD mutant demonstrated that FliD, and consequently a func-
tional ﬂagellum, is required for the colonization of mice (Haiko and
Westerlund-Wikstrom, 2013). Moreover, it has been shown that FliD
promotes bioﬁlm formation, thereby contributing toward environ-
mental resilience (Ratthawongjirakul et al., 2016). The association
between the presence of antibodies against FliD and gastric cancer is
well documented. Based on these ﬁndings, it has been suggested that
FliD can serve as a biomarker in screening for GC patients (Li et al.,
2016). We hypothesized that highly expressed proteins that are critical
for H. pylori infection might constitute optimal candidates for subunit
vaccines. In this regard, rFliD was administered orally or sub-
cutaneously and formulated with Addavax, CpG, or CTB adjuvants.
Addavax is a squalene-based oil-in-water emulsion capable of eliciting
both cellular and humoral immune responses (Ren et al., 2017; Calabro
et al., 2013). MF59, which has similar composition as Addavax, has
been approved for clinical use in the US with a seasonal ﬂu vaccine
(Tsai, 2011). By contrast, CpG oligodeoxynucleotides are toll-like re-
ceptor 9 (TLR9) agonists known to stimulate innate immune defenses
and antigen-speciﬁc T cell responses (Bode et al., 2011). CTB is a potent
adjuvant which can stimulate innate and antigen-speciﬁc responses
upon oral or intranasal administration (Stratmann, 2015).
We looked at the protective capability of rFliD by challenging vac-
cinated mice with live H. pylori SS1. Our results demonstrate that mice
immunized with rFliD in combination with any of the tested adjuvants
conferred signiﬁcant protective immunity to mice as compared to the
control group. Immunization with non-adjuvanted rFliD resulted in
partial protection against H. pylori but signiﬁcant in comparison to the
naïve control. Taken together, our results suggest that FliD is capable of
eliciting strong and protective immune responses in mice when com-
bined with adjuvants. Our results also demonstrated that the strongest
immune responses were elicited by subcutaneous rather than oral im-
munization. Since both CpG and Addavax have been approved for
human application, they may form the basis of future subunit vaccines
against H. pylori (Mohan et al., 2013; Mbow et al., 2010).
To investigate how immunity against H. pylori infection was estab-
lished, cellular immune responses were assessed by measuring cytokine
production of splenocytes from immunized mice after re-stimulation in
vitro. These cells showed robust IFN-γ secretion, which is indicative of a
Th1 type of response. Furthermore, high quantities of IL-17 were pro-
duced by splenocytes of immunized mice upon re-stimulation. These
ﬁndings are consistent with earlier studies by other investigators who
reported mixed Th1 and Th17 responses against a set of distinct H.
pylori proteins (Lv et al., 2014; Chionh et al., 2014b; Sjokvist Ottsjo
Fig. 1. Expression and puriﬁcation of recombinant
FliD. (a) Analysis of rFliD protein expression by SDS-
PAGE. Protein expression in bacteria transformed
with the ﬂid gene was induced by the addition of
IPTG to the media. Four hours after induction, the
bacteria were harvested, the bacterial lysates run
over Nickel-NTA columns and bound proteins eluted
with Imidazole. Aliquots of the diﬀerent fractions
were size-separated by SDS-PAGE and the resulting
gel stained with Coomassie-Blue. Lane 1: molecular
weight marker, lane 2: bacterial lysate after IPTG
induction, lane 3: ﬂow through of Nickel-NTA
column, lanes 4 and 5: column eluate with buﬀer
containing 20mM Imidazole, lanes 6 and 7: eluate
with buﬀer containing 40mM Imidazole, Lane 8:
eluate with buﬀer containing 1M Imidazole. (b)
Western blot analysis of rFliD using a monoclonal
antibody directed against the 6xHis-tag attached to
rFliD. Lane 1: Molecular weight marker, lane 2:
puriﬁed rFliD, lane 3: lysate of untransformed bac-
teria. Expected size of rFliD: 84 kDa.
Fig. 2. H. pylori colonization of stomach tissue in immunized mice. C57BL/6 mice were
immunized on day 0, 15 and 30 with three doses of 30 μg rFliD with CpG, Addavax, CTB
or PBS. The control groups (8 mice per each group) only received adjuvants or PBS. Two
weeks after ﬁnal vaccination (on day 45), mice were challenged orally with H. pylori. Four
weeks post challenge, levels of gastric H. pylori colonization were determined by real-time
quantitative PCR. Signiﬁcance (ANOVA) was evaluated with reference to the PBS control.
ns: not signiﬁcant, ***: p < 0.001, *: p < 0.05.
A. Ghasemi et al. Molecular Immunology 94 (2018) 176–182
179
et al., 2015; Liu et al., 2011; Chen et al., 2014). In addition, increased
amounts of IL-4 were produced by splenocytes of rFliD-immunized
versus naïve mice. However, the amount of IL-4 produced by the cells
was comparable low. Therefore, it remains unknown whether the vac-
cines also elicited a signiﬁcant Th2 type of immune response. Adjuvants
are able to modulate strength and type of the T cell response against a
given antigen. For example, adjuvants like CTB can skew immune re-
sponse from Th1 to Th2 whereas MF59® is a strong stimulator of both
Th1 and Th2 immune responses (Ott et al., 1995; Berin and Shreﬄer,
2008). As determined by cytokine secretion assays, all adjuvants em-
ployed in this study induced very similar types of cellular immune re-
sponses against rFliD that encompassed diﬀerent immune eﬀector
functions, which may explain their protective eﬀect. Although the
speciﬁc functions of the secreted cytokines in the control of H. pylori
infection still need to be elucidated in more detail, Th1 and Th17 cells
have been implicated in inducing local inﬂammation and in promoting
protective immune responses (Larussa et al., 2015). Moreover, Th17
responses are involved in the recruitment of neutrophils, the release of
antimicrobial peptides and the induction of IL-17-driven Th1 immunity
(Ray et al., 2014).
To further characterize the Th1 and Th2 proﬁle of the elicited im-
mune responses, production of antigen-speciﬁc IgG1 and IgG2a anti-
bodies was assessed. Although rFliD-induced humoral immune re-
sponses were predominantly of IgG1 isotype, signiﬁcant levels of IgG2a
titers were also detected. Speciﬁc antibodies against rFliD of both iso-
types were also produced in mice immunized with rFliD alone, but ti-
ters were signiﬁcantly lower in comparison to mice vaccinated with
rFliD and adjuvants. The elicited antibody responses in animals vacci-
nated with rFliD and adjuvants were more pronounced when applied
subcutaneously than through the oral route. To assess the mucosal
Fig. 3. Analysis of the rFliD-speciﬁc antibody response in immunized animals. (a) Kinetics of the IgG1 and IgG2a responses after immunization with rFliD plus diﬀerent adjuvants. Animals
(5 mice per each group) were bled retroorbitally on the indicated days and speciﬁc IgG1 and IgG2a antibody titers against rFliD were evaluated by ELISA. Titer values represent the
mean ± SD of sera from three analyses of ﬁve animals each. (b) Gastric scrapings were collected 45 days post ﬁrst immunization and rFliD-speciﬁc IgA titers analyzed by ELISA. Ψ:
Comparison of antigen-speciﬁc anti-rFliD IgG1 and IgG2a in mice immunized with rFliD formulated with and without adjuvant. ∮ : Comparison of anti-rFliD IgA in mice immunized with
rFliD versus PBS. ns: not signiﬁcant, *: p < 0.05, **: p < 0.01, ***: p < 0.001.
Fig. 4. Cytokine production by splenocytes from immunized mice after restimulation
with rFliD. Spleen cells of mice from all ﬁve groups (5 mice per each group) were sti-
mulated in vitro with 10 μg/mL rFliD for 48 h. Cytokine levels in culture supernatant were
measured by sandwich ELISA. The data are the mean±SD of ﬁve individual mice from
each group with two repeats. Signiﬁcance was assessed between mice immunized with
rFliD+/− adjuvants and mice treated with PBS. ***: p < 0.001.
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humoral immune response elicited by the diﬀerent vaccines, gastric IgA
production was evaluated. Immunizations with rFliD and Addavax,
CpG, or CTB induced signiﬁcant levels of antigen-speciﬁc gastric IgA
compared to control mice. These ﬁndings suggest that vaccination with
rFliD and adjuvant, regardless of subcutaneous or oral route of delivery,
eﬃciently induced gastric mucosal immune responses.
Although the immune mechanisms that provide protective im-
munity against H. pylori infection are still poorly deﬁned, cellular im-
mune responses seem to be critical and suﬃcient to provide protection
even in the absence of B cells (Ernst and Pappo, 2001). Which type of
cellular immune response is most protective is still matter of debate.
While Th1 type of responses were considered most eﬀective in previous
studies, Mohammadi et al. (Mohammadi et al., 1997) recently showed
that Th1 cells increased the severity of gastritis and Th2 cells were
required for reducing bacterial load. Likewise, Th17 type of responses
were shown to favor bacterial growth (Shi et al., 2010), while other
studies emphasized the importance of Th-17 cells and IL-17 in reducing
bacterial load. For example, DeLyria et al. (DeLyria et al., 2009) showed
that mice vaccinated against H. pylori showed robust Th-17 responses
and that protection was dependent on neutrophils. Moreover, the se-
cretion of IL-17 in mice vaccinated against H. pylori was shown to be
critical for the reduction of the bacterial load (Velin et al., 2009). In the
present study, the ratio of IgG1/IgG2a and the cytokine proﬁle of res-
timulated splenocytes from vaccinated mice are indicative of a mixed
Th1 and Th17 type of response. How precisely protective immunity is
established by the vaccine-induced immune responses is currently not
known and requires analysis of the local recall response, e.g. the pro-
duction of cytokines, especially IFN-γ and IL-17, and antimicrobial
peptides in the gastric tissue after challenge in immunized mice. Ad-
ditional experiments are also needed to assess whether vaccine eﬃcacy
can be further increased by incorporating additional H. pylori antigens.
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